The U.S. Food and Drug Administration approved the use of lumacaftor/ivacaftor (Orkambi®) today for children with cystic fibrosis ages 2 to 5 who have two copies of the F508del mutation.
Site Search
Showing 21 - 30 of 59 results
News
|
Dec. 28, 2007
|
1 min read
News
|
Nov. 21, 2007
|
2 min read
News
|
Aug. 7, 2018
|
3 min read
Tezacaftor/ivacaftor (Symdeko™) is approved for individuals with two copies of the most common cystic fibrosis mutation, F508del, as well as for individuals who have a single copy of one of 26 specified mutations -- regardless of their other mutation.
News
|
Feb. 12, 2018
|
4 min read
Celtaxsys Inc. reported promising results today from an early stage clinical trial of a potential anti-inflammatory drug for people with cystic fibrosis.
News
|
Aug. 2, 2018
|
2 min read
News
|
Oct. 4, 2006
|
2 min read
News
|
Aug. 11, 2014
|
5 min read
News
|
May 24, 2010
|
2 min read
News
|
May 17, 2010
|
3 min read
The U.S. Food and Drug Administration (FDA) approved the use of ivacaftor (Kalydeco®) today for people ages 2 and older with cystic fibrosis who have at least one of the following five splice mutations: 3849+10kbC->T, 2789+5G->A, 3272-26A->G, 711+3A->G, E831X.
News
|
Aug. 1, 2017
|
2 min read